There is an intense interest among neonatal caregivers as to whether lactoferrin given enterally may reduce the incidence of necrotizing enterocolitis in preterm infants. This review presents scientific and clinical evidence that lactoferrin alleviates or prevents this life-threatening disease.
INTRODUCTION
Lactoferrin may be the most important protein consumed by breast-fed infants immediately after birth [1 & ]. Although the volume of milk consumed is low, the content of lactoferrin in colostrum is high, up to 9 g per liter [2] . The content of lactoferrin in mature milk declines to 2-3 g per liter over time, but the intake of lactoferrin remains elevated when the term infant only receives breast milk [2] . Over 20 years ago, Lucas and Cole [3] reported that human milk significantly reduced the incidence of necrotizing enterocolitis (NEC) in very low-birth weight (VLBW) infants. Since that time, scientific investigations have provided a rationale for why lactoferrin may reduce the risk of NEC [4 & ]. We anticipate that ongoing clinical trials and data from the recent 11th International Conference on Lactoferrin will provide additional evidence for the use of lactoferrin prophylaxis in preterm infants to reduce the incidence and/or severity of NEC.
HOW LACTOFERRIN MAY REDUCE OR PREVENT NECROTIZING ENTEROCOLITIS: THE SCIENTIFIC FOUNDATION
Human milk contains substantial amounts of immunoprotective and antimicrobial substances such as lactoferrin. However, gastrointestinal (GI) immaturity and feeding intolerance limits the benefits of human milk intake in VLBW infants. Therefore, a number of investigators have proposed overcoming this problem by providing enteral lactoferrin after birth to prevent infections [5] . Known biological effects of lactoferrin include: enhanced antimicrobial activity, establishment of a healthy gut microbiome, promotion of intestinal growth and maturation, antiinflammatory activity, and enhanced development of the intestinal immune system. important than iron sequestration and bacteriostatic activity [6] . Lactoferricin (LFcin) is a potent microbicide enzymatically released from lactoferrin [7 && ]. LFcin may not be effectively generated in the stomach of preterm infants because gastric pH is initially high and pepsin content is low [1 & ]. The association of H2 blockers with NEC suggests that insufficient production of LFcin when the gastric pH is elevated may be a critical variable in increasing the risk of disease [8] . The antimicrobial activity of native lactoferrin is significantly less than that of
], yet lactoferrin can act together with other microbicidal proteins to kill microbes. A combination of lysozyme and lactoferrin causes the rapid destruction of Escherichia coli [5] . Lysozyme and other antimicrobial proteins are present in human milk [9 && ] and in neonatal salivary secretions [10]. Hence, a primary function of lactoferrin is to synergize with other swallowed antimicrobial agents in the neonatal stomach, thereby killing potential intra-gastric pathogens and allowing 'sterile' fluid to flow into the duodenum. Reducing the burden of virulent and invasive microbes and their toxic metabolites in the small intestine may be effective in preventing NEC [11] . 
Lactoferrin as a prebiotic and emergence of a healthy intestinal microbiome

Lactoferrin promotes growth and maturation of small bowel and protects enterocytes
Neonatal mice that consume milk of transgenic dams containing 12 mg/ml of human lactoferrin have enhanced growth and maturation of the intestinal mucosa [16] . Induction of anoikis (a form of programmed cell death) is another unique property of lactoferrin that protects enterocytes [17] . We observed that prophylaxis with lactoferrin followed by infection with enteral E. coli caused epithelia invaded by bacteria to undergo apoptosis. Bacteria-laden and apoptotic epithelia were released from the basement membrane and entered the gut lumen. Thereafter, the apoptotic cells with trapped bacteria exited the body in the feces, while healthy epithelia closed ranks on the mucosal surface. Accordingly, lactoferrin has direct effects on epithelia in the small bowel that protect these cells from harm.
Anti-inflammatory actions of lactoferrin in the intestine
Intestinal inflammation is classically observed in infants with NEC [18 && ]. Lactoferrin supplementation in VLBW infants may dampen intestinal inflammation through several potential mechanisms [1 & ], but human investigations have not specifically examined that issue. Lactoferrin binds bacterial peptidoglycans, lipopolysaccharides (LPS), flagellin, and CpG oligodeoxynucleotides, and, in doing so, blocks signaling via Toll-like receptors [19, 20] . In neonatal rats, rhLF prophylaxis followed by enteral infection with E. coli [5] markedly reduced villous edema in the small bowel ( Fig. 1) . Bacterial translocation is associated with villous edema, and lactoferrin pretreatment substantially reduced swelling of enterocytes. Mechanisms by which lactoferrin is anti-inflammatory in the neonatal intestine require more research.
Effects of lactoferrin on intestinal immune system development
Enteral rhLF prophylaxis given to neonatal rats [5] significantly accelerated the development of Peyer's
KEY POINTS
Antimicrobial activity of lactoferrin differs in preterm neonates compared with adults.
Anti-inflammatory actions of lactoferrin may help prevent necrotizing enterocolitis.
Lactoferrin enhances maturation of the neonatal immune system to resist infection.
No lactoferrin preparation is currently available for use in preterm infants. Prevention of neonatal infections by early feeding of maternal colostrum is the latest approach. patches (Fig. 1) . Calves demonstrate the same phenomenon with a lower content of pro-inflammatory cytokines in blood following enterally administered lactoferrin [21] . Increased secretory immunoglobulin A (SIgA) production may be responsible for these observations. B-cells in gutassociated lymphoid tissues release SIgA into the bowel lumen, and this limits the attachment and invasion of intestinal epithelia by bacteria [22 & ]. Lactoferrin also binds endotoxin, altering its inflammatory nature, as the lactoferrin-LPS complex can either prime or activate immune cells [23 & ]. Thus, lactoferrin may awaken an immunosuppressed intestinal immune system in neonates that is a holdover of the fetal habitat [24] . Mechanisms associated with rhLF-related maturation of immature dendritic cells have recently been described [25 & ]. Figure 2 illustrates in detail relationships between lactoferrin and immune cells in the small bowel. It is imprudent to extrapolate the effects of lactoferrin on adult immune cells to the newborn. Additional research will tell us how lactoferrin modulates development of the nascent immune system in the GI tract. 
PRE-CLINICAL STUDIES OF LACTOFERRIN AND PREVENTION OF NECROTIZING ENTEROCOLITIS
Neonatal animal models of NEC have not used lactoferrin to reduce the severity of or in the prevention of disease. Supplements of lactoferrin to prevent nosocomial infection in preterm infants began with commercial availability of rhLF [26] . Two animal models investigated whether prophylaxis with lactoferrin diminished bacterial translocation in the small intestine. Edde and colleagues showed that feeding rhLF followed by massive gut infection with E. coli significantly lowered bacteremia, improved health status and prevented death [5] . LF-related immune activation in the gut was likely responsible for this effect. Sherman et al. [27] showed that prophylaxis with rhLF and Lactobacillus rhamnosus GG (LGG) substantially reduced bacterial translocation after intestinal infection with enteroinvasive E. coli. Microbial invasion of the sub-mucosa is necessary for the pathognomonic signature of NEC, pneumatosis intestinalis, which signifies a poor prognosis [18 && ].
CLINICAL STUDIES OF LACTOFERRIN AND PREVENTION OF NECROTIZING ENTEROCOLITIS
RCTs to prove lactoferrin reduces NEC have not been undertaken. NEC has been a secondary outcome in studies that examined whether lactoferrin prevented late-onset sepsis (LOS). Manzoni et al. [28] reported that bovine lactoferrin (bLF) reduced LOS in VLBW infants from 17.3% with placebo to 5.9% with bLF. Prophylaxis with bLF and LGG had an additional beneficial effect in reducing LOS. The maximal value in lowering the rate of LOS was observed in preterm infants weighing less than 1.0 kg at birth. Supplementation with bLF and LGG showed a trend towards reducing NEC. Manzoni 
SUMMARY AND FUTURE DIRECTIONS
Lactoferrin is a multifunctional protein. Its activities in the intestine are the basis for the inference that NEC might be made less severe or prevented by feeding this protein. There is no lactoferrin preparation approved by the Food and Drug Administration for use in preterm infants. A mother's colostrum fed soon after birth is the best alternative when a lactoferrin supplement is not available for VLBW infants. The practice appears safe [29,30 & ], but the optimal route of delivery and whether early colostrum reduces the severity or the prevalence of NEC in immature human infants necessitates more research. 
